Management of Newly Diagnosed Primary Central Nervous System Lymphoma
DOI:
https://doi.org/10.58931/cht.2025.4274Abstract
The last decade has witnessed significant progress in the clinical management of patients with newly diagnosed primary central nervous system (CNS) diffuse large B-cell lymphoma (PCNS-DLBCL, hereafter referred to as PCNSL). Data from several clinical trials have demonstrated the potential for long-term remission in a proportion of patients, particularly those eligible for intensive multi-agent chemotherapy approaches. High-dose methotrexate (HD‑MTX)‑based induction regimens remain standard-of-care globally for both younger and older patients with newly diagnosed PCNSL. However, with clinical trial data demonstrating the efficacy of multiple regimens (differing in partner chemotherapy agents, hematological toxicity, and MTX dose density), but with few randomized comparisons, the optimal induction regimen remains unclear.
Consolidation therapy is key to survival outcomes in PCNSL. Thiotepa-based autologous stem cell transplantation (TT-ASCT) has been widely adopted as the consolidation therapy of choice for patients ≤70 years. However, it is increasingly recognized that appropriately selected patients older than 70 years can also benefit from TT-ASCT consolidation. In parallel, declining rates of whole-brain radiotherapy (WBRT) have been observed due to significant risk of neurotoxicity, particularly in patients aged ≥60 years.
This review summarises the contemporary clinical management of patients with newly diagnosed PCNSL. We focus on key diagnostic considerations, the landscape of evidence-based first-line treatments, and practical guidance for treatment selection and delivery. We also briefly discuss specific scenarios, including human immunodeficiency virus (HIV)-associated PCNSL and vitreoretinal involvement in the context of PCNSL.
References
Ferreri AJM, Cwynarski K, Pulczynski E, Fox CP, Schorb E, Celico C, et al. Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial. Leukemia. 2022 Jul;36(7):1870–8. DOI: https://doi.org/10.1038/s41375-022-01582-5
Houillier C, Dureau S, Taillandier L, Houot R, Chinot O, Moluçon-Chabrot C, et al. Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients Age 60 Years and Younger: Long-Term Results of the Randomized Phase II PRECIS Study. J Clin Oncol. 2022 Nov 10;40(32):3692–8. DOI: https://doi.org/10.1200/JCO.22.00491
Batchelor TT, Giri S, Ruppert AS, Geyer SM, Smith SE, Mohile N, et al. Myeloablative vs nonmyeloablative consolidation for primary central nervous system lymphoma: results of Alliance 51101. Blood Adv. 2024 Jun 25;8(12):3189–99. DOI: https://doi.org/10.1182/bloodadvances.2023011657
Schorb E, Isbell LK, Kerkhoff A, Mathas S, Braulke F, Egerer G, et al. High-dose chemotherapy and autologous haematopoietic stem-cell transplantation in older, fit patients with primary diffuse large B-cell CNS lymphoma (MARTA): a single-arm, phase 2 trial. Lancet Haematol. 2024 Mar;11(3):e196–205. DOI: https://doi.org/10.1016/S2352-3026(23)00371-X
Schorb E, Fox CP, Fritsch K, Isbell L, Neubauer A, Tzalavras A, et al. High-dose thiotepa-based chemotherapy with autologous stem cell support in elderly patients with primary central nervous system lymphoma: a European retrospective study. Bone Marrow Transplant. 2017 Aug;52(8):1113–9. DOI: https://doi.org/10.1038/bmt.2017.23
Ferreri AJM, Calimeri T, Cwynarski K, Dietrich J, Grommes C, Hoang-Xuan K, et al. Primary central nervous system lymphoma. Nat Rev Dis Primer. 2023 Jun 15;9(1):29. DOI: https://doi.org/10.1038/s41572-023-00439-0
Tosefsky K, Rebchuk AD, Martin KC, Chen DW, Yip S, Makarenko S. Preoperative Corticosteroids Reduce Diagnostic Accuracy of Stereotactic Biopsies in Primary Central Nervous System Lymphoma: A Systematic Review and Meta-Analysis. Neurosurgery. 2024 Oct;95(4):740–50. DOI: https://doi.org/10.1227/neu.0000000000002944
WHO Classification of Tumours Editorial Board. Haematolymphoid tumours [Internet] [Internet]. 5th ed.; vol. 11. Lyon (France): International Agency for Research on Cancer; 2024 [cited 2024 Mar 27]. (WHO classification of tumours series). Available from: https://tumourclassification.iarc.who.int/chapters/63
Soussain C, Malaise D, Cassoux N. Primary vitreoretinal lymphoma: a diagnostic and management challenge. Blood. 2021 Oct 28;138(17):1519–34. DOI: https://doi.org/10.1182/blood.2020008235
Schmitt AM, Herbrand AK, Fox CP, Bakunina K, Bromberg JEC, Cwynarski K, et al. Rituximab in primary central nervous system lymphoma—A systematic review and meta‐analysis. Hematol Oncol. 2019 Dec;37(5):548–57. DOI: https://doi.org/10.1002/hon.2666
Martinez‐Calle N, Poynton E, Alchawaf A, Kassam S, Horan M, Rafferty M, et al. Outcomes of older patients with primary central nervous system lymphoma treated in routine clinical practice in the UK: methotrexate dose intensity correlates with response and survival. Br J Haematol. 2020 Aug;190(3):394–404. DOI: https://doi.org/10.1111/bjh.16592
Giraud EL, De Lijster B, Krens SD, Desar IME, Boerrigter E, Van Erp NP. Dose recommendations for anticancer drugs in patients with renal or hepatic impairment: an update. Lancet Oncol. 2023 Jun;24(6):e229. DOI: https://doi.org/10.1016/S1470-2045(23)00216-4
Wendler J, Lewis RI, Kutilina A, Knott M, Isbell LK, Valk E, et al. Pre-phase treatment with rituximab and high-dose methotrexate to re-evaluate eligibility for intensive induction treatment of frail patients with central nervous system lymphoma. Haematologica [Internet]. 2025 Jan 23 [cited 2025 Aug 21]; Available from: https://haematologica.org/article/view/11907 DOI: https://doi.org/10.3324/haematol.2024.286347
Illerhaus G, Ferreri AJM, Binder M, Borchmann P, Hasenkamp J, Stilgenbauer S, et al. Effects on Survival of Non-Myeloablative Chemoimmunotherapy Compared to High-Dose Chemotherapy Followed By Autologous Stem Cell Transplantation (HDC-ASCT) As Consolidation Therapy in Patients with Primary CNS Lymphoma - Results of an International Randomized Phase III Trial (MATRix/IELSG43). Blood. 2022 Dec 6;140(Supplement 2):LBA-3. DOI: https://doi.org/10.1182/blood-2022-171733
Schorb E, Fox CP, Kasenda B, Linton K, Martinez‐Calle N, Calimeri T, et al. Induction therapy with the MATRix regimen in patients with newly diagnosed primary diffuse large B‐cell lymphoma of the central nervous system – an international study of feasibility and efficacy in routine clinical practice. Br J Haematol. 2020 Jun;189(5):879–87. DOI: https://doi.org/10.1111/bjh.16451
Fox CP, Phillips EH, Smith J, Linton K, Gallop‐Evans E, Hemmaway C, et al. Guidelines for the diagnosis and management of primary central nervous system diffuse large B‐cell lymphoma. Br J Haematol. 2019 Feb;184(3):348–63. DOI: https://doi.org/10.1111/bjh.15661
Fox CP, Ali AS, McIlroy G, Thomas CM, Kassam S, Wright J, et al. A phase 1/2 study of thiotepa-based immunochemotherapy in relapsed/ refractory primary CNS lymphoma: the TIER trial. 2021;5(20). DOI: https://doi.org/10.1182/bloodadvances.2021004779
Arshad S, Fang X, Ahn KW, Kaur M, Scordo M, Sauter CS, et al. Impact of thiotepa dose-intensity in primary diffuse large B-cell lymphoma of the central nervous system undergoing autologous hematopoietic cell transplant with thiotepa/carmustine conditioning. Bone Marrow Transplant. 2023 Nov;58(11):1203–8 DOI: https://doi.org/10.1038/s41409-023-02071-8
Scordo M, Wang TP, Ahn KW, Chen Y, Ahmed S, Awan FT, et al. Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant. JAMA Oncol. 2021 Jul 1;7(7):993.
Schorb E, Kasenda B, Ihorst G, Scherer F, Wendler J, Isbell L, et al. High-dose chemotherapy and autologous stem cell transplant in elderly patients with primary CNS lymphoma: a pilot study. Blood Adv. 2020 Jul 28;4(14):3378–81. DOI: https://doi.org/10.1182/bloodadvances.2020002064
Wendler J, Fox CP, Valk E, Steinheber C, Fricker H, Isbell LK, et al. Optimizing MATRix as remission induction in PCNSL: de-escalated induction treatment in newly diagnosed primary CNS lymphoma. BMC Cancer. 2022 Sep 10;22(1):971. DOI: https://doi.org/10.1186/s12885-022-09723-w
Fritsch K, Kasenda B, Schorb E, Hau P, Bloehdorn J, Möhle R, et al. High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study). Leukemia. 2017 Apr;31(4):846–52. DOI: https://doi.org/10.1038/leu.2016.334
Omuro A, Chinot O, Taillandier L, Ghesquieres H, Soussain C, Delwail V, et al. Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial. Lancet Haematol. 2015 Jun;2(6):e251–9. DOI: https://doi.org/10.1016/S2352-3026(15)00074-5
Omuro AMP, DeAngelis LM, Karrison T, Bovi JA, Rosenblum M, Corn BW, et al. Randomized phase II study of rituximab, methotrexate (MTX), procarbazine, vincristine, and cytarabine (R-MPV-A) with and without low-dose whole-brain radiotherapy (LD-WBRT) for newly diagnosed primary CNS lymphoma (PCNSL). J Clin Oncol. 2020 May 20;38(15_suppl):2501–2501. DOI: https://doi.org/10.1200/JCO.2020.38.15_suppl.2501
Hübel K, Bower M, Aurer I, Bastos-Oreiro M, Besson C, Brunnberg U, et al. Human immunodeficiency virus-associated lymphomas: EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2024 Oct;35(10):840–59. DOI: https://doi.org/10.1016/j.annonc.2024.06.003
Abrey LE, Batchelor TT, Ferreri AJM, Gospodarowicz M, Pulczynski EJ, Zucca E, et al. Report of an International Workshop to Standardize Baseline Evaluation and Response Criteria for Primary CNS Lymphoma. J Clin Oncol. 2005 Aug 1;23(22):5034–43. DOI: https://doi.org/10.1200/JCO.2005.13.524
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Canadian Hematology Today
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
